Digene SurePath “Not-Approvable” Letter Expected After FDA Data Request

Digene will be required to submit additional clinical data to FDA to support its application for use of TriPath's SurePath test pack as a specimen collection medium for the Hybrid Capture 2 (HC2) human papillomavirus (HPV) test